Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2024/04/066435
CTRI/2024/04/066435Not yet recruitingPhase 4

A Study of the Efficacy and Safety of Combination of Omega-3 Fatty Acids and Vitamin E versus Combined Oral Contraceptive Pills in Polycystic Ovarian Syndrome - NI

Pandit B. D. Sharma UHS Rohtak0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1.Females of age group (15-45 years).
  • •2.Subjects diagnosed with PCOS according to modified 2018 criteria (Rotterdam criteria): Presence of 2 out of 3 traits.
  • •a.v Presence of Hyperandrogenism (clinical and/or biochemical)
  • •b.v Oligo/Anovulation
  • •c.v PCOM (Polycystic ovarian morphology)- at least one ovary with
  • •i=20 follicles per ovary in either ovary
  • •ii=10 cm3 of ovarian volume
  • •3.Patients willing to give written informed consent/assent.

Exclusion Criteria

  • •1.Any history of Neoplastic disease.
  • •2.Endocrinal disorders like Hyperprolactinemia, Hyper/ Hypo Thyroidism and Acromegaly.
  • •3.Functional Hypothalamic amenorrhoea.
  • •4.Already on PCOS treatment or have taken Vitamin supplements in the last 3 months.
  • •5.Females who are either pregnant, willing to become pregnant or lactating.
  • •6.Any Chronic Liver or renal disease.

Investigators

Sponsor
Pandit B. D. Sharma UHS Rohtak

Similar Trials

Completed
Not Applicable
Investigation on efficacy and safety of combination treatment with imidafenacin and mirabegron in patients with overactive bladder.overactive bladder
JPRN-UMIN000016236Clinical Research Support Center Kyushu30
Completed
Phase 2
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcomasoft tissue cancer10072990
NL-OMON39691Morphotek, Inc10
Active, not recruiting
Phase 1
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.
EUCTR2012-001399-12-NLMorphotek Inc.200
Active, not recruiting
Phase 1
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.Metastatic Soft Tissue SarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-001399-12-BEMorphotek Inc.200
Completed
Not Applicable
Effect of the combination of artificial dura and umbilical cord and placenta mesenchymal stem cell-derived exosomes in patients with complete spinal cord injuryComplete spinal cord injury.Injury of spinal cord, level unspecifiedT09.3
IRCT20200502047277N1Shahid Beheshti University of Medical Sciences60